GH:NSD-Guardant Health Inc (USD)

COMMON STOCK | Diagnostics & Research |

Last Closing

USD 43.14

Change

0.00 (0.00)%

Market Cap

USD 4.85B

Volume

1.17M

Analyst Target

USD 110.00
Analyst Rating

Verdict

ducovest Verdict
Created with Highstock 5.0.6

Verdict

About

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
GH QQQ
  • QQQ
Relative Returns (From:    To: 2025-03-30 )

Largest Industry Peers for Diagnostics & Research

Symbol Name Price(Change) Market Cap
IDXX IDEXX Laboratories Inc

+7.68 (+1.83%)

USD 33.82B
NTRA Natera Inc

+2.55 (+1.81%)

USD 21.03B
ICLR ICON PLC

+2.14 (+1.28%)

USD 14.94B
ILMN Illumina Inc

+3.49 (+4.45%)

USD 14.06B
MEDP Medpace Holdings Inc

+13.50 (+4.53%)

USD 9.97B
EXAS EXACT Sciences Corporation

+1.11 (+2.55%)

USD 8.47B
RDNT RadNet Inc

+1.89 (+3.73%)

USD 3.68B
SHC Sotera Health Co

+0.37 (+3.32%)

USD 3.23B
WGS GeneDx Holdings Corp.

+0.28 (+0.33%)

USD 2.75B
VCYT Veracyte Inc

+0.57 (+1.93%)

USD 2.48B

ETFs Containing GH

ARKG:LSE ARK Genomic Revolution UC.. 5.83 % 0.00 %

+0.01 (+0.32%)

USD 9.33M
ARCG:LSE ARK Genomic Revolution UC.. 5.01 % 0.00 %

+0.10 (+0.32%)

USD 9.51M
DOCG:LSE L&G Healthcare Breakthrou.. 2.41 % 0.00 %

-5.45 (0.32%)

USD 0.06B
DOCT:LSE L&G Healthcare Breakthrou.. 2.41 % 0.00 %

-0.03 (0.32%)

USD 0.06B
DOCT:SW L&G Healthcare Breakthrou.. 2.21 % 0.00 %

+0.07 (+0.32%)

USD 0.06B
FESM Fidelity Covington Trust 0.70 % 0.00 %

+0.48 (+0.32%)

USD 2.22B
ARKG ARK Genomic Revolution ET.. 0.00 % 0.75 %

+0.67 (+0.32%)

USD 1.06B
FNY First Trust Mid Cap Growt.. 0.00 % 0.70 %

+1.15 (+0.32%)

USD 0.43B
HTEC Robo Global® Healthcare .. 0.00 % 0.00 %

+0.32 (+0.32%)

USD 0.05B
XHS SPDR® S&P Health Care Se.. 0.00 % 0.35 %

+0.46 (+0.32%)

USD 0.08B

Market Performance

  Market Performance vs. Industry/Classification (Diagnostics & Research) Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain 41.21% 96% N/A 95% A
Dividend Return N/A N/A N/A N/A N/A
Total Return 41.21% 96% N/A 95% A
Trailing 12 Months  
Capital Gain 109.11% 91% A- 96% N/A
Dividend Return N/A N/A N/A N/A N/A
Total Return 109.11% 91% A- 96% N/A
Trailing 5 Years  
Capital Gain -38.02% 45% F 26% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -38.02% 41% F 25% F
Average Annual (5 Year Horizon)  
Capital Gain -15.69% 35% F 16% F
Dividend Return -15.69% 35% F 16% F
Total Return N/A N/A N/A N/A N/A
Risk Return Profile  
Volatility (Standard Deviation) 49.83% 63% D 37% F
Risk Adjusted Return -31.49% 31% F 20% F
Market Capitalization 4.85B 86% B+ 88% B+

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Rating

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
High market capitalization

This is one of the largest entities in its sector and is among the top quartile. Such companies tend to be more stable.

Superior Revenue Growth

This stock has shown top quartile revenue growth in the previous 5 years compared to its sector.

What to not like:
Poor risk adjusted returns

This company is delivering below median risk adjusted returns in its peers. Even if it is outperforming on returns , the returns are unpredictable. Proceed with caution.

Overpriced compared to book value

The stock is trading high compared to its peers median on a price to book value basis.

Below median dividend returns

The company’s average income yield over the past 5 years has been low compared to its peers. However, it is not a problem if you are not looking for income.

Negative cashflow

The company had negative total cash flow in the most recent four quarters.

Negative free cash flow

The company had negative total free cash flow in the most recent four quarters.

Low Earnings Growth

This stock has shown below median earnings growth in the previous 5 years compared to its sector